Cited by 655Medication Adherence and ComplianceDiabetes Management and EducationDiabetes Management and Research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Open access

Peyrot, M., Barnett, A. H., Meneghini, L. F., Schumm‐Draeger, P.‐M.·2012·Diabetic Medicine

DOI 10.1111/j.1464-5491.2012.03605.xPMC PMC3433794

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens. METHODS: Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat patients with diabetes and telephone survey of 1530 insulin-treated patients (180 with Type 1 diabetes, 1350 with Type 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, the UK or the USA. RESULTS: One third (33.2%) of patients reported insulin omission/non-adherence at least 1 day in the last month, with an average of 3.3 days. Three quarters (72.5%) of physicians report that their typical patient does not take their insulin as prescribed, with a mean of 4.3 days per month of basal insulin omission/non-adherence and 5.7 days per month of prandial insulin omission/non-adherence. Patients and providers indicated the same five most common reasons for insulin omission/non-adherence: too busy; travelling; skipped meals; stress/emotional problems; public embarrassment. Physicians reported low patient success at initiating insulin in a timely fashion and adjusting insulin doses. Most physicians report that many insulin-treated patients do not have adequate glucose control (87.6%) and that they would treat more aggressively if not for concern about hypoglycaemia (75.5%). Although a majority of patients (and physicians) regard insulin treatment as restrictive, more patients see insulin treatment as having positive than negative impacts on their lives. CONCLUSIONS: Glucose control is inadequate among insulin-treated patients, in part attributable to insulin omission/non-adherence and lack of dose adjustment. There is a need for insulin regimens that are less restrictive and burdensome with lower risk of hypoglycaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03605.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

FIGURE 1 Physician report: patient success with insulin treatment tasks (n = 1250)*†. *Percentage of physicians reporting that their patients are very successful (vs. somewhat successful, not very successful, not at all successful, ‘don’t know’). †Specialists and primary care physicians not significantly different for any measureCC BY · PubMed Central

FIGURE 2 Patient reports: impact of insulin treatment on life domains in patients with Type 1 (non-hatched) and Type 2 (hatched) diabetes mellitus (n = 1530). *Positive and negative responses differ significantly (P < 0.05); †reports from patients with Type 1 and Type 2 diabetes differ significantly (P < 0.05).CC BY · PubMed Central

FIGURE 3 Physician beliefs about insulin treatment (n = 1250). *Strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree, neither, ‘don’t know’); †strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree)CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study
Peyrot, M., Rubin, R. R., Lauritzen, T., Snoek, F. J., Matthews, D. R., & Skovlund, S. E. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01644.x · Cited by 931
Self-citation
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M. F., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 784
Self-citation
Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Self-citation
Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 403
Psychological insulin resistance: patient beliefs and implications for diabetes management
Brod, M. I., Kongsø, J. H., Alolga, S. L., & Christensen, T. L. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9419-1 · Cited by 238
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers
Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.02.004 · Cited by 159

Show all 22 references

Sorted by citations

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
Davies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 302
Medication Adherence With Diabetes Medication
Capoccia, K. L., Odegard, P. S., & Letassy, N. A. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715619038 · Cited by 292
New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G.-H., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 254
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O'Neil, P. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 253
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
Ritzel, R. A., Roussel, R., Bolli, G. B., Vinet, L., Brulle-Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12485 · Cited by 236
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
Chou, D. H., Webber, M. J., Tang, B. C., Lin, A. B., Thapa, L. S., Deng, D., Truong, J. V., Cortinas, A. B., Langer, R., & Anderson, D. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424684112 · Cited by 237
Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
Khunti, K., & Millar-Jones, D. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2016.09.003 · Cited by 238
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“Similar to all insulin analogues, the risk of hypoglycaemia is a major safety concern, and is considered a key obstacle in regulating blood glucose levels by both patients and physicians [10, 57].”
Background
The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily
Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Self-citation
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial
Lingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220
Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219
Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
Okemah, J., Peng, J., & Quiñones, M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0819-5 · Cited by 211
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Rosenstock, J., BAJAJ, H. S., Janež, A., Silver, R., Begtrup, K., Hansen, M. V., Jia, T., & Goldenberg, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022474 · Cited by 206
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jódar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 197
Glucose-Responsive Nanoparticles for Rapid and Extended Self-Regulated Insulin Delivery
Volpatti, L. R., Matranga, M. A., Cortinas, A. B., Delcassian, D., Daniel, K. B., Langer, R., & Anderson, D. G. (2019) · ACS Nano · doi:10.1021/acsnano.9b06395 · Cited by 198
Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
Khunti, S., Khunti, K., & Seidu, S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819844694 · Cited by 182
Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (ONSET 1)
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
on behalf of the DEVOTE Study Group, Zinman, B., Marso, S. P., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Lange, M., Brown‐Frandsen, K., Moses, A. C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4423-z · Cited by 170
pH-sensitive MOF integrated with glucose oxidase for glucose-responsive insulin delivery
Zhang, C., Hong, S., Liu, M., Yu, W., Zhang, M., Zhang, L., Zeng, X., & Zhang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.038 · Cited by 171
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Rosenstock, J., Bain, S. C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., Nishida, T., Trevisan, R., & Mosenzon, O. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303208 · Cited by 170
Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes
Elleri, D., Allen, J. M., Kumareswaran, K., Leelarathna, L., Nodale, M., Caldwell, K., Cheng, P., Kollman, C., Haidar, A., Murphy, H. R., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0816 · Cited by 158
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
Nishimura, E., Pridal, L., Glendorf, T., Hansen, B. F., Hubálek, F., Kjeldsen, T., Kristensen, N. R., Lützen, A., Lyby, K., Madsen, P., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002301 · Cited by 159
Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes
Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
Factors associated with injection omission/non‐adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study
Peyrot, M. F., Barnett, A. H., Meneghini, L., & Schumm‐Draeger, P. ‐. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01636.x · Cited by 144
Self-citation
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
Philis‐Tsimikas, A., Asong, M., Franek, E., Jia, T., Rosenstock, J., Stachlewska, K., Watada, H., & Kellerer, M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00093-1 · Cited by 146
Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen
Adolfsson, P., Hartvig, N. V., Kaas, A., Møller, J. B., & Hellman, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0411 · Cited by 139
Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review
Andreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
BAJAJ, H. S., Bergenstal, R. M., Christoffersen, A., Davies, M. J., Gowda, A., Isendahl, J., Lingvay, I., Senior, P. A., Silver, R., Trevisan, R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2877 · Cited by 124
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
Spain, C. V., Wright, J. J., Hahn, R., Wivel, A. E., & Martin, A. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.009 · Cited by 120
Improved Medication Adherence and Frequency of Blood Glucose Self-Testing Using an m-Health Platform Versus Usual Care in a Multisite Randomized Clinical Trial Among People with Type 2 Diabetes in India
Kleinman, N. J., Shah, A., Shah, S., Phatak, S., & Viswanathan, V. (2017) · Telemedicine and e-Health · doi:10.1089/tmj.2016.0265 · Cited by 116
Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in E urope and the USA
Mauricio, D., Meneghini, L., Seufert, J., Liao, L., Wang, H., Tong, L., Cali, A. M. G., Stella, P., Carita, P., & Khunti, K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12927 · Cited by 115
Self-citation
Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
Fulcher, G. R., Christiansen, J. S., Bantwal, G., Polaszewska-Muszyńska, M., Mersebach, H., Andersen, T. H., & NISKANEN, L. K. (2014) · Diabetes Care · doi:10.2337/dc13-2908 · Cited by 111
Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial ( EDITION JP 2)
Terauchi, Y., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., & Hirose, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12618 · Cited by 106
Smart approaches to glucose-responsive drug delivery
Webber, M. J., & Anderson, D. G. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1055749 · Cited by 103
Perceptions of insulin use in type 2 diabetes in primary care: a thematic synthesis
Ellis, K., Mulnier, H. E., & Forbes, A. (2018) · BMC Family Practice · doi:10.1186/s12875-018-0753-2 · Cited by 101
Benefits and Challenges of Diabetes Technology Use in Older Adults
Toschi, E., & Munshi, M. N. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.001 · Cited by 100
Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
Gabbay, R. A., Kendall, D., Beebe, C., Cuddeback, J. K., Hobbs, T. M., Khan, N. D., Leal, S., Miller, E. M., Novak, L. M., Rajpathak, S. N., et al. (2020) · Clinical Diabetes · doi:10.2337/cd20-0053 · Cited by 91
Self-citation
Technology in the management of type 2 diabetes: Present status and future prospects
DALY, A. B., & Hovorka, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14418 · Cited by 100
Electrically controlled release of insulin using polypyrrole nanoparticles
Hosseini-Nassab, N., Samanta, D., Abdolazimi, Y., Annes, J. P., & Zare, R. N. (2016) · Nanoscale · doi:10.1039/c6nr08288b · Cited by 90
Exploring the role of the patient–physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study
Linetzky, B., Jiang, D., Funnell, M. M., Curtis, B. H., & Polonsky, W. H. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12443 · Cited by 89
Identifying and meeting the challenges of insulin therapy in type 2 diabetes
SORLI, C. H., & HEILE, M. K. (2014) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s64084 · Cited by 95
Glycaemic control for people with type 2 diabetes in Saudi Arabia – an urgent need for a review of management plan
Alramadan, M. J., Magliano, D. J., Almigbal, T. H., Batais, M. A., Afroz, A., Alramadhan, H. J., Mahfoud, W. F., Alragas, A. M., & Billah, B. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0292-9 · Cited by 91
Use of Voice-Based Conversational Artificial Intelligence for Basal Insulin Prescription Management Among Patients With Type 2 Diabetes
Nayak, A., Vakili, S., Nayak, K., Nikolov, M. C., Chiu, M., Sosseinheimer, P., Talamantes, S., Testa, S., Palanisamy, S., Giri, V. K., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.40232 · Cited by 89
Barriers and solutions to diabetes management: An Indian perspective
Wangnoo, S., Maji, D., Das, A., Rao, P., Moses, A., Sethi, B. K., Unnikrishnan, A., Kalra, S., Balaji, V., Bantwal, G., et al. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113749 · Cited by 85
Why do some people with type 2 diabetes who are using insulin have poor glycaemic control? A qualitative study
Tong, W. T., Vethakkan, S. R., & Ng, C. J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006407 · Cited by 81
Glucose and H 2 O 2 dual-sensitive nanogels for enhanced glucose-responsive insulin delivery
Li, C., Liu, X., Liu, Y., Huang, F., Wu, G., Liu, Y., Zhang, Z., Ding, Y., Lv, J., Ma, R., et al. (2019) · Nanoscale · doi:10.1039/c9nr01554j · Cited by 81
Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens
Yavuz, D. G., Özcan, S., & Deyneli, O. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87935 · Cited by 80
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 83
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses
Brod, M., Rana, A., & Barnett, A. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.743458 · Cited by 77
Self-citation
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
Heise, T., Nosek, L., Roepstorff, C., Chenji, S., Klein, O., & Haahr, H. L. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0070-2 · Cited by 75
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes
Heise, T., Chien, J. Y., Beals, J. M., Benson, C., Klein, O., Moyers, J. S., Haupt, A., & Pratt, E. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14956 · Cited by 75
Missed and Mistimed Insulin Doses in People with Diabetes: A Systematic Literature Review
Robinson, S., Newson, R. S., Liao, B., Kennedy-Martin, T., & Battelino, T. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0164 · Cited by 73
“16,18 Physicians included in GAPP1 and in another U.S. survey indicated that a high proportion of PwD missed insulin doses or failed to take insulin as prescribed (Table 2).”
Influential
Clinical use of insulin degludec
Vora, J. P., Cariou, B., Evans, M., Gross, J. L., Harris, S. B., Landstedt‐Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
Self-citation
Glucose-responsive insulin release: Analysis of mechanisms, formulations, and evaluation criteria
Yang, J., & Cao, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.043 · Cited by 74
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes
Ritzel, R. A., Roussel, R., Giaccari, A., Vora, J. P., Brulle-Wohlhueter, C., & Yki‐Järvinen, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13105 · Cited by 75
Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters-Weijnen, C., Forsén, T., Galstyan, G., Geelhoed-Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.004 · Cited by 71
Assessment of medication self-administration using artificial intelligence
Zhao, M., Hoti, K., Wang, H., Raghu, A., & Katabi, D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01273-1 · Cited by 70
Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial
Giugliano, D., Longo, M., Caruso, P., Di Fraia, R., Scappaticcio, L., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Diabetes Care · doi:10.2337/dc20-2623 · Cited by 69
“However, insulin therapy is burdened by challenging issues, such as the risk of hypoglycemia, weight gain, and the complexity of injectable treatment (2).”
Background
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
Philis‐Tsimikas, A., Billings, L. K., Busch, R. S., Morales, C., Sahay, R. K., Halladin, N., Eggert, S., Begtrup, K., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13666 · Cited by 69
Glucose and H2O2 Dual-Responsive Polymeric Micelles for the Self-Regulated Release of Insulin
Liu, X., Li, C., Lv, J., Huang, F., An, Y., Shi, L., & Ma, R. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01185 · Cited by 68
Level of sustained glycemic control and associated factors among patients with diabetes mellitus in Ethiopia: a hospital-based cross-sectional study
Abebe, S. M., Berhane, Y., Worku, A., Alemu, S., & Mesfin, N. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s75467 · Cited by 68
Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil
Gomes, M. B., & Negrato, C. A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.011 · Cited by 68
Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. Insulin glargine: A meta-analysis of seven clinical trials
Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.005 · Cited by 66
Microgel encapsulated nanoparticles for glucose-responsive insulin delivery
Volpatti, L. R., Facklam, A. L., Cortinas, A. B., Lu, Y., Matranga, M. A., MacIsaac, C., Hill, M. C., Langer, R., & Anderson, D. G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120458 · Cited by 65
Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
Rate of glycemic control and associated factors among type two diabetes mellitus patients in Ethiopia: a cross sectional study
Nigussie, S., Birhan, N., Amare, F., Mengistu, G., Adem, F., & Abegaz, T. M. (2021) · PLOS ONE · doi:10.1371/journal.pone.0251506 · Cited by 62
“Starting insulin therapy for T2DM patients often showed blood glucose level is not well controlled [41, 42].”
Background
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
Frías, J. P., Chien, J. Y., Zhang, Q., Chigutsa, E., Landschulz, W. H., Syring, K. E., Wullenweber, P. K., Haupt, A., & KAZDA, C. M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00388-6 · Cited by 64
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
Wysham, C., BAJAJ, H. S., Prato, S. D., Franco, D. R., Kiyosue, A., Dahl, D. B., Zhou, C., Carr, M. C., Case, M. G., & GONCALVES, L. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403953 · Cited by 61
Challenges and recent advances in the subcutaneous delivery of insulin
Guo, X., & Wang, W. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1232247 · Cited by 61
Injectable self-assembled peptide hydrogels for glucose-mediated insulin delivery
Fu, M., Zhang, C., Dai, Y., Li, X., Pan, M., Huang, W., Qian, H., & Ge, L. (2018) · Biomaterials Science · doi:10.1039/c8bm00006a · Cited by 57
Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes
Wei, W., Pan, C., Xie, L., & Başer, O. (2013) · Endocrine Practice · doi:10.4158/ep13159.or · Cited by 56
Adherence to treatment for diabetes mellitus: validation of instruments for oral antidiabetics and insulin
Boas, L. C. G.-V., de Lima, M. L. S. A. P., & Pace, A. E. (2014) · Revista Latino-Americana de Enfermagem · doi:10.1590/0104-1169.3155.2386 · Cited by 54
Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus
Edelman, S. V., & Pettus, J. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.003 · Cited by 56
Stimuli-responsive self-assembled dendrimers for oral protein delivery
Zeng, Z., Qi, D., Yang, L., Liu, J., Tang, Y., Chen, H., & Feng, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.049 · Cited by 53
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes
Riddle, M. C., Bolli, G. B., Home, P., Bergenstal, R. M., Ziemen, M., Muehlen-Bartmer, I., Wardęcki, M., Vinet, L., Jeandidier, N., & Yki‐Järvinen, H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0290 · Cited by 50
Hypoglycemia: New Definitions and Regulatory Implications
Ratner, R. E. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0113 · Cited by 52
A randomized controlled trial of the efficacy and safety of saxagliptin as add‐on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J. T., Visvanathan, J., Montanaro, M., & Fisher, S. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12234 · Cited by 49
Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
Philis‐Tsimikas, A., Brod, M. I., Niemeyer, M., Francisco, A. M. O., & Rothman, J. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0036-1 · Cited by 48
Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals
Leiter, L. A., Boras, D., & Woo, V. C. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.270 · Cited by 48
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Wardęcki, M., Goyeau, H., & Home, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.007 · Cited by 48
Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review
Rodriguez, P., Martin, V. T. S., & Pantalone, K. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01530-9 · Cited by 55
The current and future roles of community pharmacists: Views and experiences of patients with type 2 diabetes
Twigg, M. J., Poland, F. M., Bhattacharya, D., Desborough, J., & Wright, D. J. (2012) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2012.10.004 · Cited by 48
Electrothermal patches driving the transdermal delivery of insulin
Pagneux, Q., Ye, R., Li, C., Barras, A., Hennuyer, N., Staels, B., Caina, D., Osses, J. A., Abderrahmani, A., Plaisance, V., et al. (2019) · Nanoscale Horizons · doi:10.1039/c9nh00576e · Cited by 48
The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives
Ceriello, A., de Valk, H. W., Guerci, B., Haak, T., Owens, D. R., Canobbio, M., Fritzen, K., Stautner, C., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108053 · Cited by 50
Glucagon prescription patterns in patients with either type 1 or 2 diabetes with newly prescribed insulin
Mitchell, B. D., He, X., Sturdy, I. M., Cagle, A. P., & Settles, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15831.or · Cited by 46
Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c
Mitchell, B. D., Vietri, J., Zagar, A. J., Curtis, B. H., & Reaney, M. D. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-59 · Cited by 46
Blood Glucose Measurement in the Intensive Care Unit: What is the Best Method?
Le, H. T., Harris, N., Estilong, A. J., Olson, A., & Rice, M. J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700226 · Cited by 44
A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
Haahr, H. L., Fita, E. G., & Heise, T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0455-7 · Cited by 45
A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study
McGovern, A. P., Hinton, W., Calderara, S., Munro, N. M., Whyte, M., & de Lusignan, S. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0361-5 · Cited by 47
Automated meal detection from continuous glucose monitor data through simulation and explanation
Zheng, M., Ni, B., & Kleinberg, S. (2019) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz159 · Cited by 45

Authors: Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐.
Affiliations: Johns Hopkins University (US)
Heart of England NHS Foundation Trust (GB)
University of Miami (US)
München Klinik Bogenhausen (DE)
Corresponding author: Peyrot, M.
ORCID: Peyrot, M.
Meneghini, L. F.
Venue: Diabetic Medicine
Publisher: Wiley
Published: 2012-04-16
Volume: 29
Issue: 5
Pages: 682-689
ISSN: 0742-3071 (ISSN-L)
1464-5491
DOI: 10.1111/j.1464-5491.2012.03605.x
PMC: PMC3433794
OpenAlex: W1613501644
Cited by: 655
References: 22
Citations by year: 2026: 29 · 2025: 41 · 2024: 61 · 2023: 43 · 2022: 42 · 2021: 43 · 2020: 53 · 2019: 49 · 2018: 52 · 2017: 48 · 2016: 52 · 2015: 50 · 2014: 46 · 2013: 35 · 2012: 8
FWCI: 38.62
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetic Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: insulin therapy, insulin adherence, insulin omission, barriers to adherence, patient beliefs, physician beliefs, type 1 diabetes, type 2 diabetes, glycemic control, hypoglycemia, basal insulin, prandial insulin, insulin dose adjustment
MeSH terms: Assessment of Medication Adherence, Blood Glucose, China, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, France, Germany, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Japan, Male, Middle Aged, Spain, Turkey, United States, Health Behavior, Drug Monitoring, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks